Autologous peripheral blood stem cell transplantation for Japanese multiple myeloma patients: results of a feasibility study

• NAKAMURA Yuichi

  Department of Hematology, Dokkyo University School of Medicine

• SAKAMAKI Hisashi

  Hematology Division, Metropolitan Komagome Hospital

• MUKAI Harumi

  Division of Hematology, Institute of Clinical Medicine, University of Tsukuba

• KOJIMA Hiroshi

  Division of Hematology, Institute of Clinical Medicine, University of Tsukuba

• TOMIYAMA Junji

  Department of Internal Medicine, Metropolitan Bokuto Hospital

• MORI Shin-ichirou

  Hematology Division, Metropolitan Komagome Hospital

• HIRUMA Kiyoshi

  Blood Transfusion Service, Metropolitan Komagome Hospital

• NAKAMURA Norihiko

  Department of Internal Medicine, Yokosuka Kyosai Hospital

• TOYOTA Shigeo

  Department of Internal Medicine, Yokosuka Kyosai Hospital

• HAMAGUCHI Hiroyuki

  Department of Internal Medicine, Musashino Red Cross Hospital

• DAN Kazuo

  Third Department of Internal Medicine, Nippon Medical School

• MITANI Kinuko

  Department of Hematology, Dokkyo University School of Medicine

• SAITO Kenji

  Department of Hematology, Dokkyo University School of Medicine

Bibliographic Information

Other Title

• 多発性骨髄腫に対する自家末梢血幹細胞移植療法
• 臨床研究 多発性骨髄腫に対する自家末梢血幹細胞移植療法--本邦でのプロトコールの実行性についての検討
• リンショウ ケンキュウ タハツセイ コツズイシュ ニ タイスル ジカ マッショウケツ カンサイボウ イショク リョウホウ ホンポウ デ ノ プロトコール ノ ジッコウセイ ニ ツイテ ノ ケントウ
• —本邦でのプロトコールの実行性についての検討—

Abstract

A feasibility study on high-dose therapy with autologous peripheral blood stem cell transplantation (HDT/PBSCT) was performed in Japanese patients with multiple myeloma (MM). Twenty evaluable patients younger than 65 years old with stage II/III MM were enrolled in this study. Three courses of VAD were used as initial chemotherapy. High-dose etoposide or cyclophosphamide followed by G-CSF was used for PBSCH, and 1.2-89.3 (median 23.4)×10⁶/kg of CD34⁺ cells were collected. Single (11 patients) or tandem (9 patients) HDT with melphalan (MEL) 200 mg/m² or MEL 140 mg/m² plus TBI 10 Gy were performed. The incidence of grade 4 toxicity (JCOG) was 10% and treatment-related mortality was 5%. Complete response and tumor reduction of more than 75% were obtained in 4 (21%) and 16 (84%) out of 19 patients, respectively. The actuarial 3-year overall survival (OS) and event-free survival (EFS) after PBSCT/HDT were 65.6% and 22.0%, respectively. The median EFS duration was 18 months. These preliminary results indicated that HDT/PBSCT is feasible for Japanese MM patients. A prospective randomized clinical trial will be required to assess the efficacy.

Journal

• Rinsho Ketsueki

  Rinsho Ketsueki 45 (7), 524-529, 2004

  The Japanese Society of Hematology

Keywords

• Multiple myeloma
• Autologous peripheral blood stem cell transplantation
• High dose therapy

Details

• CRID: 1390001205033003776
• NII Article ID: 10013335569
• NII Book ID: AN00252940
• DOI: 10.11406/rinketsu.45.524
• COI: 1:STN:280:DC%2BD2cvltFyjsg%3D%3D
• ISSN: 18820824
• ISSN: 04851439
• NDL BIB ID: 7039985
• PubMed: 15359911
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I7039985
• Web Site: https://search.jamas.or.jp/link/ui/2005001958
• Text Lang: ja
• Data Source:
  • JaLC
  • NDL
  • PubMed
  • CiNii Articles
• Abstract License Flag: Disallowed